D. Close

3.9k total citations · 1 hit paper
26 papers, 3.0k citations indexed

About

D. Close is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, D. Close has authored 26 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 10 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Immunology. Recurrent topics in D. Close's work include Rheumatoid Arthritis Research and Therapies (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Systemic Lupus Erythematosus Research (5 papers). D. Close is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Systemic Lupus Erythematosus Research (5 papers). D. Close collaborates with scholars based in United States, United Kingdom and Germany. D. Close's co-authors include Jonathan Edwards, L Szczepański, Jacek Szechiński, Tim Shaw, Paul Emery, Randall M. Stevens, Anna Filipowicz‐Sosnowska, David Jayne, A. Godwood and Venkat Reddy and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and The Laryngoscope.

In The Last Decade

D. Close

25 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

2004 1.9k citations Jonathan Edwards, L Szczepański et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Close United States	15	1.5k	1.2k	807	548	442	26	3.0k
Tim Shaw United States	9	1.3k 0.9×	902 0.8×	640 0.8×	576 1.1×	463 1.0×	16	2.5k
Anna Filipowicz‐Sosnowska Poland	8	1.8k 1.2×	1.1k 0.9×	798 1.0×	728 1.3×	588 1.3×	36	3.4k
Edward M Vital United Kingdom	34	2.6k 1.7×	2.0k 1.6×	995 1.2×	434 0.8×	333 0.8×	147	3.9k
Hans‐Peter Tony Germany	32	1.6k 1.1×	2.1k 1.8×	685 0.8×	660 1.2×	803 1.8×	151	4.4k
Satoshi Kubo Japan	32	1.6k 1.1×	1.2k 1.0×	252 0.3×	368 0.7×	454 1.0×	157	3.0k
Diane van der Woude Netherlands	32	2.8k 1.9×	1.1k 0.9×	1.4k 1.7×	343 0.6×	463 1.0×	85	4.1k
David Hagerty United States	19	1.3k 0.9×	1.6k 1.3×	470 0.6×	340 0.6×	627 1.4×	34	4.2k
E. Hessey United Kingdom	6	1.7k 1.1×	732 0.6×	615 0.8×	710 1.3×	650 1.5×	8	2.4k
Arnaud Constantin France	30	1.9k 1.3×	829 0.7×	269 0.3×	329 0.6×	605 1.4×	120	3.1k
Gurtej S. Cheema United States	24	1.3k 0.9×	1.2k 1.0×	411 0.5×	172 0.3×	283 0.6×	26	2.9k

Countries citing papers authored by D. Close

Since Specialization

Citations

This map shows the geographic impact of D. Close's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Close with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Close more than expected).

Fields of papers citing papers by D. Close

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Close. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Close. The network helps show where D. Close may publish in the future.

Co-authorship network of co-authors of D. Close

This figure shows the co-authorship network connecting the top 25 collaborators of D. Close. A scholar is included among the top collaborators of D. Close based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Close. D. Close is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Andrews, Janet I., Thomas Kuri̇akose, Lawrence J. Scaletta, et al.. (2024). OP0110 AZD1163 - FIRST-IN-CLASS ANTI-PAD2/4 BI-SPECIFIC ANTIBODY TO INHIBIT AUTOANTIGEN FORMATION IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 83. 54–54.

Burmester, Gerd R, Iain B. McInnes, Joel M. Kremer, et al.. (2018). Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody. Arthritis & Rheumatology. 70(5). 679–689. 62 indexed citations

Weinblatt, Michael E., Iain B. McInnes, Joel M. Kremer, et al.. (2017). A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis & Rheumatology. 70(1). 49–59. 72 indexed citations

Burmester, Gerd R, Iain B. McInnes, Joel M. Kremer, et al.. (2017). A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases. 76(6). 1020–1030. 105 indexed citations

Guo, Xiang, Brandon W. Higgs, Anne‐Christine Bay‐Jensen, et al.. (2017). Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. Lara D. Veeken. 57(1). 175–184. 28 indexed citations

Weinblatt, Michael E., Iain B. McInnes, Joel M. Kremer, et al.. (2016). SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 75. 717–718. 4 indexed citations

Burmester, Gerd R, Iain B. McInnes, Joel M. Kremer, et al.. (2016). FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 75. 510–510. 1 indexed citations

Wu, Chi‐Sheng, et al.. (2015). AB0445 Exposure–Efficacy Analysis of Mavrilimumab in Rheumatoid Arthritis: Modeling and Simulation of Phase II Clinical Data. Annals of the Rheumatic Diseases. 74. 1043–1043. 3 indexed citations

Kremer, J.M., Gerd R Burmester, Michael E. Weinblatt, et al.. (2015). FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-Alpha, In the Phase IIB Earth Explorer 1 Study. Annals of the Rheumatic Diseases. 74. 483–484. 3 indexed citations

10.

Takeuchi, Tsutomu, et al.. (2014). Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study. Modern Rheumatology. 25(1). 21–30. 30 indexed citations

11.

Reddy, Venkat, David Jayne, D. Close, & David Isenberg. (2013). B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Research & Therapy. 15(Suppl 1). S2–S2. 112 indexed citations

12.

Kiviniemi, Marc T., Jennifer L. Hay, Aimee S. James, et al.. (2009). Decision Making about Cancer Screening: An Assessment of the State of the Science and a Suggested Research Agenda from the ASPO Behavioral Oncology and Cancer Communication Special Interest Group. Cancer Epidemiology Biomarkers & Prevention. 18(11). 3133–3137. 20 indexed citations

13.

Nair, Salil, et al.. (2004). The Effect of β‐Blocker Premedication on the Surgical Field During Endoscopic Sinus Surgery. The Laryngoscope. 114(6). 1042–1046. 107 indexed citations

14.

Edwards, Jonathan, L Szczepański, Jacek Szechiński, et al.. (2004). Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. New England Journal of Medicine. 350(25). 2572–2581. 1950 indexed citations breakdown →

15.

Kew, Jacqueline, et al.. (2002). Multiplanar Reconstructed Computed Tomography Images Improves Depiction and Understanding of the Anatomy of the Frontal Sinus and Recess. American Journal of Rhinology. 16(2). 119–123. 40 indexed citations

16.

Close, D.. (2001). Matrix metalloproteinase inhibitors in rheumatic diseases. Annals of the Rheumatic Diseases. 60. iii62–iii67. 80 indexed citations

17.

Close, D., Alan R. Kristal, Sue Li, Ruth E. Patterson, & Emily White. (1998). Associations of demographic and health-related characteristics with prostate cancer screening in Washington State.. PubMed. 7(7). 627–30. 46 indexed citations

18.

Pazdur, Richard, et al.. (1994). Phase II trial of piroxantrone in metastatic gastric adenocarcinoma. Investigational New Drugs. 12(3). 263–265. 4 indexed citations

19.

O’Reilly, Jacqueline, et al.. (1987). The Effects of Formulation and Addition of Adrenaline to Cocaine for Haemostasis in Intranasal Surgery. Anaesthesia and Intensive Care. 15(2). 141–146. 10 indexed citations

20.

Benz, Michael R., et al.. (1986). Access to day programs and leisure activities by nursing home residents with mental retardation.. PubMed. 24(3). 147–52. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact